Screener
Amneal Pharmaceuticals, Inc. AMRX Increase in tax receivable agreement liability
Increase in tax receivable agreement liability at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept amrx:IncreaseDecreaseInTaxReceivableAgreementLiability.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001723128-26-000031
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Interest expense, net | (55,043) | (65,101) | (108,404) | (122,040) |
| Foreign exchange (loss) gain, net | (1,950) | 8,256 | (9,750) | 12,503 |
| Loss on refinancing | — | — | (3,510) | — |
| Increase in tax receivable agreement liability | (2,439) | (4,420) | (106) | (15,107) |
| Other income, net | 653 | 1,604 | 1,395 | 2,122 |
| Total other expense, net | (58,779) | (59,661) | (120,375) | (122,522) |
| Income before income taxes | 70,990 | 51,711 | 151,166 | 89,197 |
| Provision for income taxes | 1,376 | 16,101 | 3,552 | 28,969 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Amneal Pharmaceuticals, Inc.'s increase in tax receivable agreement liability?
- Amneal Pharmaceuticals, Inc. (AMRX) reported increase in tax receivable agreement liability of -$2.44M in Q2 2026.
- How has Amneal Pharmaceuticals, Inc.'s increase in tax receivable agreement liability changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s increase in tax receivable agreement liability increased by 44.8% year-over-year, from -$4.42M to -$2.44M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s increase in tax receivable agreement liability?
- Over 3 years (2022 to 2025), Amneal Pharmaceuticals, Inc.'s increase in tax receivable agreement liability has grown at a 118.6% compound annual growth rate (CAGR), from -$631K to -$6.59M.
- What does increase in tax receivable agreement liability mean?
- Increase in tax receivable agreement liability as reported by Amneal Pharmaceuticals, Inc. Class A Common Stock.
Ask your AI about Amneal Pharmaceuticals, Inc.'s increase in tax receivable agreement liability.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude